OneChain Immunotherapeutics is a spin-off company from the Josep Carreras Leukemia Research Institute and ICREA, based on research led by Dr. Pablo Menéndez's team. OneChain aims to develop CAR-T candidates as a treatment for oncological diseases.

Pipeline

OC-1

CART CD1a Immunotherapy

T-ALL comprises 10–15% of all acute leukemias diagnosed in children and 20–25% in adults, with a median diagnostic age of 9 years. Survival of patients with T-ALL treated with intensive chemotherapy remains less than 70%, and relapsed/refractory (r/r) T-ALL has a particularly poor outcome of 6% to 20% in 5 to 10 years. OC-1 is a CART CD1a Immunotherapy developed as a treatment for refractory relapsed patients with cortical T-ALL, a T-ALL subgroup without many options to date. OC-1 received Orphan Drug Designation (ODD) from the EMA in 2021.

OC-2

CART CD22 Immunotherapy

B-ALL is the most common cancer in children and despite current 5-year disease-free survival rates of 80%, relapsed/refractory (r/r) patients still have a dismal outcome. B-ALL is less frequent in adults and still associated with unfavorable clinical outcomes. OC-2 immunotherapy, based on a bispecific CART, is an alternative treatment to salvage chemotherapy followed by autologous stem cell transplantation only suitable for 50% of eligible patients with r/r B-ALL.

OC-3

Novel γδ T cells allogeneic platform

Recently, γδ T cells have emerged as an alternative to αβ T cells for cellular immunotherapy. They are not constrained by MHC presentation of tumor‐associated peptides but, providing robust and durable antitumor responses. OneChain platform is a novel and efficient method for a selective, large‐scale generation of human cytotoxic Vδ1+ γδ T cells. They are very attractive candidates for adoptive cell therapy of cancer. Vδ1 naïve cells are produced in a TCR-independent manner and expanded to induce Vδ1+ T cell proliferation, which allows for a significant-fold expansion.

OC-4

Dual CART against GBM

Glioblastoma multiforme (GBM) is the most common and most aggressive primary brain tumor in humans, presenting an annual incidence of 3.2 cases per 100,000 individuals (U.S). Patients with GBM have a poor prognosis due to the current limited therapeutic approach, resulting in 5-year survival rates between 6% and 27% (2001-2015). OC-4 is a new immunotherapy against GBM, consisting of a dual CAR-T cell strategy targeting IL13Ra2-expressing GBM tumor cells and a key component of the immunosuppressive tumor microenvironment.

Stage of Development

OC-1
Target
CD1a
Indication
T-ALL
Development
Preclinical
Clinical
OC-2
Target
CD22
Indication
B-ALL
Development
Preclinical
Clinical
OC-3
Target
Allogeneic
Indication
Any
Development
Preclinical
Clinical
OC-4
Target
Il13a2/OC-4.2
Indication
GBM
Development
Preclinical
Clinical

Vision

To create a better, healthier world for people with cancer.

Mission

To discover, develop and deliver innovative therapeutics for patients suffering from oncological diseases.

Core Values

Integrity Doing What’s Right
Teamwork Working Together
Accountability Taking Personal Responsibility
Excellence Being Your Best

Board of directors

Albert Carreras

Albert Carreras

Trustee of Josep Carreras Foundation

Albert Ferrer

Albert Ferrer

Partner InVivo Capital

Laura Rodríguez

Laura Rodríguez

Principal Invivo Capital

Pablo Menéndez

Pablo Menéndez

Founder and CSO

Jorge Alemany

Jorge Alemany

CEO

Team

Pablo Menéndez

Pablo Menéndez

Founder and CSO

Jorge Alemany

Jorge Alemany

CEO

Wilmar Castillo Ávila

Wilmar Castillo Ávila

Project Manager

Víctor M. Díaz Cortés

Víctor M. Díaz Cortés

Research Director

Laura García Pérez

Laura García Pérez

Senior Research Scientist

Estibaliz Glaría Percaz

Estibaliz Glaría Percaz

Research Scientist

Natalia Ruiz Gómez

Natalia Ruiz Gómez

Laboratory Manager

Julia Cyran

Julia Cyran

Industrial PhD candidate

Sergi Casadó

Sergi Casadó

Research Scientist

OneChain' stakeholders

We count with the support of cutting-efge organizations from the private and public sector

Founder

Dr. Menéndez, is world renowned for his work in the field of childhood leukaemia. Directs the Josep Carreras Institute's stem cell biology, leukaemia development and immunotherapy group. More than 180 of his studies have been published by the world's most prestigious scientific journals. Awarded by the triennial ED Thomas Postdoctoral Fellowship, by the Josep Carreras Foundation, and three times by the European Research Council (ERC), the most important scientific funding organisation in Europe.

Investors

Seed round in July 2020

Institutions

Spin-off from Josep Carreras Foundation. The projects have been supported by the following institutions

Programa Torres Quevedo
Subprograma estatal Torres Quevedo de la Agencia Estatal de Investigación del Ministerio de Ciencia, Innovación y Universidades

PTQ2020-011056
PTQ2020-011053

Contact

Office

C/ Muntaner 383, 3rd 2nd 08021 Barcelona Spain

Laboratory

Parc Científic de Barcelona. Cluster II, C/Baldiri Reixac, 4-12 i 15, 08028 Barcelona

Write us an email
administracion@onechaintx.com